We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The Glasgow Prognostic Score Predicts Survival in Patients with Advanced Non-Small Cell Lung Cancer Harboring Sensitive Epidermal Growth Factor Receptor Mutations Who Are Treated with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors.
- Authors
Akazawa, Yuki; Igawa, Satoshi; Yamada, Kaori; Yamamoto, Hiroki; Yagami, Yuri; Kaizuka, Nobuki; Manaka, Hiroya; Kasajima, Masashi; Nakahara, Yoshiro; Sato, Takashi; Mitsufuji, Hisashi; Yokoba, Masanori; Kubota, Masaru; Sasaki, Jiichiro; Naoki, Katsuhiko
- Abstract
Introduction: Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are the standard first-line treatment for advanced non-small cell lung cancer (NSCLC) with sensitive EGFR mutations. The Glasgow prognostic score (GPS) is an inflammation-assessing score based on C-reactive protein and albumin concentrations. Information regarding the association between the GPS and EGFR-TKI treatment effectiveness is limited; hence, we investigated whether the GPS can predict the response of NSCLC to EGFR-TKIs. Methods: We evaluated 340 patients with NSCLC harboring sensitive EGFR mutations who received EGFR-TKI monotherapy between March 2009 and July 2021. The Kaplan-Meier method and Cox proportional hazards models were used to assess progression-free survival (PFS) and overall survival (OS). Results: After a median follow-up of 26.6 months, patients with a GPS of 0, 1, and 2 had PFS of 15.7, 10.0, and 6.3 months, respectively, and OS of 40.1, 25.8, and 14.4 months, respectively; patients with a GPS of 0 had significantly better PFS and OS than those with a GPS of 1 (p = 0.03, p = 0.001, respectively) or 2 (p < 0.001, p < 0.001, respectively). Multivariate analysis identified poor performance status, stage 4 at diagnosis, type of EGFR-TKI (gefitinib/erlotinib vs. afatinib), and GPS = 2 as predictors of a short PFS. Meanwhile, poor performance status, gefitinib/erlotinib administration, and GPS = 2 were predictors of a short OS. Conclusion: The GPS predicted the survival of NSCLC patients harboring sensitive EGFR mutations who were undergoing EGFR-TKI treatment. The GPS might be ideal for routine use in clinical practice, given that it is an easily calculated parameter.
- Subjects
LUNG cancer; GENETIC mutation; EPIDERMAL growth factor receptors; MULTIVARIATE analysis; PROTEIN-tyrosine kinase inhibitors; KAPLAN-Meier estimator; SURVIVAL analysis (Biometry); PROGRESSION-free survival; PROPORTIONAL hazards models; OVERALL survival
- Publication
Oncology, 2023, Vol 101, Issue 11, p685
- ISSN
0030-2414
- Publication type
Article
- DOI
10.1159/000530809